USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266 info@sofpromed.com
Select Page

What Is the Timeline for an IND Amendment? FDA Requirements

Patricio Ledesma

Sofpromed's CEO and Founder. Global Director of Clinical Operations. 15+ years of experience in managing clinical trials.

16 November, 2026

Patricio Ledesma presenting FDA requirements and timelines for IND amendments

By Patricio Ledesma, Founder and CEO, Sofpromed

Table of Contents

I'm Patricio Ledesma.

Today I want to answer a very common question:

How long does an IND amendment take with the FDA?

The answer is:

It depends on the type of amendment.

And many people are surprised to learn that not all IND amendments require waiting for FDA approval before implementation.

Let's look at what the regulations actually say.

What Is an IND Amendment?

An IND is an Investigational New Drug application.

Once an IND is active, sponsors often need to make changes.

Examples include:

  • New protocols
  • New clinical studies
  • Manufacturing changes
  • New safety information
  • Investigator updates

These changes are generally submitted as IND amendments.

FDA Citation

The FDA describes amendments to an IND under:

21 CFR 312.30 - Protocol Amendments

21 CFR 312.31 - Information Amendments

21 CFR 312.32 - IND Safety Reports

Protocol Amendments

Let's begin with protocol amendments.

These are among the most common submissions.

Examples include:

  • New clinical protocols
  • New study arms
  • Changes in eligibility criteria
  • Significant protocol modifications

According to FDA regulations:

Sponsors should submit protocol amendments before implementing the changes.

However, unlike the original IND submission:

There is generally no requirement to wait 30 days after submitting a protocol amendment before proceeding.

The FDA may review the amendment and provide comments later.

FDA Citation

21 CFR 312.30(b) states that a sponsor shall submit a protocol amendment describing any new protocol or significant protocol change.

Practical Timeline

For most protocol amendments:

  • Submission: Day 0
  • Study activities may often proceed after submission
  • FDA review may occur over the following weeks or months

The exact timing depends on the complexity of the change.

Information Amendments

Some amendments simply provide new information.

Examples include:

  • New laboratory findings
  • Additional pharmacology data
  • Chemistry updates
  • Manufacturing information

These are called Information Amendments.

FDA Citation

21 CFR 312.31

The regulation allows sponsors to submit important new information that is relevant to the IND.

Typical Timeline

Most information amendments do not trigger a formal FDA approval process.

The agency reviews the information as part of its ongoing oversight of the IND.

Safety Amendments and IND Safety Reports

Patient safety always comes first.

If an important safety issue is identified, sponsors must act quickly.

Examples include:

  • Serious adverse events
  • Unexpected toxicities
  • New safety findings from related studies

FDA Citation

According to 21 CFR 312.32:

Sponsors must rapidly report certain serious and unexpected suspected adverse reactions.

Typical Timeline

Some reports must be submitted:

  • Within 7 calendar days
  • Within 15 calendar days

depending on the nature of the safety finding.

These timelines are regulatory reporting requirements, not FDA review timelines.

Manufacturing Changes (CMC Amendments)

Now let's discuss manufacturing changes.

These can be more complicated.

Examples:

  • New manufacturing site
  • New formulation
  • Process changes
  • Changes in raw materials
  • New stability data

The FDA carefully evaluates whether these changes affect:

  • Safety
  • Identity
  • Strength
  • Quality
  • Purity
  • Potency

FDA Citation

CMC updates are commonly submitted under:

21 CFR 312.31 (Information Amendments)

The specific content requirements are also addressed throughout 21 CFR Part 312.

Typical Timeline

Minor changes may receive little FDA feedback.

Major changes may generate:

  • Information requests
  • Clarification requests
  • Safety questions

Timelines can range from several weeks to several months.

When Does the 30-Day FDA Review Clock Apply?

This is where many sponsors become confused.

The famous 30-day waiting period usually applies to:

The original IND submission.

FDA Citation

Under 21 CFR 312.40(b):

A clinical investigation may begin 30 days after FDA receives the IND unless FDA notifies the sponsor otherwise.

This regulation applies primarily to the initial IND.

It does not automatically apply to every amendment submitted afterward.

That is a very important distinction.

Could an Amendment Trigger a Clinical Hold?

Yes.

The FDA can place a study on clinical hold if significant concerns arise.

FDA Citation

21 CFR 312.42 - Clinical Holds

Reasons may include:

  • Human subject safety concerns
  • Insufficient information
  • Manufacturing concerns
  • Unreasonable risk

If a clinical hold is issued, implementation timelines become much longer.

The sponsor must address all FDA concerns before moving forward.

Realistic Planning for Sponsors

When planning your study timelines, I recommend:

For simple amendments:

  • Plan for administrative review only.

For moderate amendments:

  • Build in several weeks for potential FDA questions.

For major CMC or safety-related amendments:

  • Build in several months of contingency.

Never assume that FDA silence means no future questions.

Always be inspection-ready.

Always maintain complete documentation.

Key Takeaways

Let's summarize.

An IND amendment does not have one universal timeline.

Protocol amendments are usually submitted before implementation.

Information amendments generally do not require prior FDA approval.

Safety reports have strict reporting deadlines.

Major manufacturing changes may receive extensive FDA scrutiny.

And remember:

The 30-day waiting period typically applies to the original IND, not to routine IND amendments.

Infographic showing timelines for IND protocol amendments, information amendments, safety reports and manufacturing updates

Figure 1: How long does an IND amendment take?

Conclusion

So, what is the timeline for an IND amendment?

The answer depends on the type of amendment and the potential impact on patient safety.

The best strategy is simple:

Prepare high-quality submissions.

Provide strong supporting data.

And anticipate FDA questions before they arise.

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com